Skip to content
Research
The overarching goal of the Ulloa lab is to develop novel therapeutic strategies to improve treatment paradigms and clinical outcomes for children and adults with deadly, often drug-tolerant or -resistant infections for which proven therapies are limited and no guidance from clinical trials exist. With this framework in mind, we examine: (A) Drugs that boost the antibacterial killing capacity of human immune factors; (B) Drug repurposing for difficult-to-treat bacterial infections; and (C) Antibiotic activity under physiologically modeled conditions.
*This page is under construction*
